Beyond nutrition: Neuropeptide signaling and muscle mass maintenance in chronic kidney disease

Kidney International

Volumn 74, Issue 2, 2008, Pages 143-145

  Roberts, Tiffany K ^a,b   Bailey, James L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; JANUS KINASE; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; NEUROPEPTIDE; STAT PROTEIN;

CACHEXIA; CHRONIC KIDNEY DISEASE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; NOTE; NUTRITION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 46249130518     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.220     Document Type: Note

References (12)

1. Cheung WW, Rosengren S, Boyle DL, Mak RH. Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int 2008; 74: 180-186.
2. Cheung W, Yu PX, Little BM et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115: 1659-1665.
3. Stenvinkel P, Lindholm B, Lönnqvist F et al. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11: 1303-1309.
4. Yang R, Barouch LA. Leptin signaling and obesity: cardiovascular consequences. Circ Res 2007; 101: 545-559.
5. Mak RH, Cheung W. Cachexia in chronic kidney disease: role of inflammation and neuropeptide signaling. Curr Opin Nephrol Hypertens 2007; 16: 27-31.
6. Cheung W, Yu PX, Little BM et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115: 1659-1665.
7. Mitch WE. Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure. J Ren Nutr 2006; 16: 208-211.
8. Heszele MFC, Price SR. Insulin-like growth factor I: the yin and yang of muscle atrophy. Endocrinology 2004; 145: 4803-4805.
9. Joulia-Ekaza D, Cabello G. The myostatin gene: physiology and pharmacological relevance. Curr Opin Pharmacol 2007; 7: 310-315.
10. Tan JC, Rabkin R. Suppressors of cytokine signaling in health and disease. Pediatr Nephrol 2005; 20: 567-575.
11. Bjørbæk C, Buchholz RM, Davis SM et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001; 276: 4747-4755.
12. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788.